AbbVie recommends shareholders reject offer to sell stake to investment group

A capital investment firm is attempting to buy 1.5 million shares of AbbVie common stock at $88.05 per share in a mini-tender offer. 

What you should know:

1. TRC Capital Investment Corp., has turned its eye to AbbVie as the latest target of its mini-tender investment strategy. The firm has developed a reputation for its mini-tender investment strategy, where it attempts to secure a small minority ownership by buying stock for under-market value, according to an article on Seeking Alpha

2. AbbVie released a statement recommending shareholders don't sell to TRC. 

3. AbbVie recommends shareholders obtain current share quotes, review terms and conditions, and consult with their stockbroker before taking any action. 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast